0000899243-19-009670.txt : 20190402
0000899243-19-009670.hdr.sgml : 20190402
20190402200200
ACCESSION NUMBER: 0000899243-19-009670
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190313
FILED AS OF DATE: 20190402
DATE AS OF CHANGE: 20190402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BLECH ISAAC
CENTRAL INDEX KEY: 0000905536
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 19727174
MAIL ADDRESS:
STREET 1: C/O INSPIREMD, INC.
STREET 2: 321 COLUMBUS AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 955 MASSACHUSETTS AVENUE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 955 MASSACHUSETTS AVENUE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2019-03-13
2019-03-14
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0000905536
BLECH ISAAC
C/O X4 PHARMACEUTICALS, INC.
955 MASSACHUSETTS AVENUE, 4TH FLOOR
CAMBRIDGE
MA
02139
1
0
0
0
Stock Option (right to buy)
6.84
2019-03-13
4
A
0
70796
A
2025-12-14
Common Stock
70796
70796
D
Stock Option (right to buy)
18.66
2019-03-13
4
A
0
6854
0.00
A
2029-03-13
Common Stock
6854
6854
D
Fully vested.
Reflects the Reporting Person's stock option to acquire 744,967 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger").
33.3333% of the shares subject to the option shall vest on March 13, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the award, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to report this additional stock option grant, which was granted automatically on March 13, 2019 pursuant to the Issuer's Director Compensation Policy upon such Reporting Person's election to the Board of Directors of the Issuer in connection with the closing of the Merger.
All share and per share amounts of the Issuer's common stock and stock options reported in this Form 4/A reflect the 1-for-6 reverse stock split of the Issuer's common stock effected on March 13, 2019 after the completion of the Merger.
/s/ Adam S. Mostafa, attorney-in-fact
2019-04-02